WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

Previous ATC codeATC level nameNew ATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
L01EX17 capmatinib L01EP01 01.02.20252026
L01EX21 tepotinib L01EP02 01.02.20252026
L04AA58efgartigimod alfaL04AL0101.02.20252026
L04AG16rozanolixizumabL04AL0201.02.20252026

Last updated: 2024-12-11